Bark is an acronym for beta-adrenergic receptor kinase, an enzyme that has recently been found in tissues throughout the body in one form or another.

Gleevec was originally designed to inhibit a receptor kinase called PDGFR-beta, which is hyperactive in glioma, a brain cancer.

The cr4 gene codes for a receptor kinase and so is involved in signal transduction pathways involving the fate of aleurone cells.

BRI1-associated receptor kinase 1 (BAK1), is a plant protein.

This may be due to a polymorphism in African-American patients of the G-protein-coupled receptor kinase (GRK5) that confers a natural "genetic beta-blockade".

The beta-adrenergic receptor kinase specifically phosphorylates the agonist-occupied form of the beta-adrenergic and related G protein-coupled receptors.

This protein can also be phosphorylated by activin type 1 receptor kinase, and mediates the signal from the activin.

PDE6G has been shown to interact with Beta adrenergic receptor kinase and Src.

Arrestin beta 1 is a cytosolic protein and acts as a cofactor in the beta-adrenergic receptor kinase (BARK) mediated desensitization of beta-adrenergic receptors.

GRK2 (G-protein-coupled receptor kinase 2)